Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate

Immunology

Volumn 119, Issue 3, 2006, Pages 348-354

  Mullen, Alexander B ^a   Lawrence, Catherine E ^a   McFarlane, Emma ^a   Wei, Xiao Quing ^b   Carter, Katharine C ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

IL 18; Leishmania donovani; Sodium stibogluconate

Indexed keywords

CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; INFECTION SENSITIVITY; LEISHMANIA DONOVANI; LEISHMANIASIS; LIVER; MOUSE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; TH1 CELL; WILD TYPE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; SPLEEN; TH1 CELLS; TREATMENT OUTCOME;

EID: 33750022387     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02438.x     Document Type: Article

References (28)

1. Dinarello C, Fantuzzi G. Interleukin 18 and host defence. J Infectious Dis 2003; 187:S370-S384.
2. Tsutsui H, Adachi K, Seki E, Nakanishi K. Cytokine-induced inflammatory liver injuries. Current Mol Med 2003; 3:545-59.
3. Helmby H, Grencis RK. IL-18 regulates intestinal mastocytosis and Th2 cytokine production independently of IFN-γ during Trichinella spiralis infection. J Immunol 2002; 169:2553-60.
4. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166:517-21.
5. Cai G, Kastelein R, Hunter CA. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000; 68:6932-8.
6. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol 1997; 159:5528-34.
7. Mastroeni P, Clare S, Khan S, Harrison JA, Hormaeche CE, Okamura H, Kurimoto M, Dougan G. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect Immun 1999; 67:478-83.
8. Wei XQ, Leung BP, Niedbala W et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163: 2821-8.
9. Van Der Sluijs KF, Van Elden LJ, Arens R et al. Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. Immunology 2005; 114:112-20.
10. Helmby H, Takeda K, Akira S, Grencis RK. Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. J Exp Med 2001; 194:355-64.
11. Xu D, Trajkovic V, Hunter D, Leung BP, Schulz K, Gracie JA, McInnes IB, Liew FY. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000; 30:3147-56.
12. Melby PC, Tabares A, Restrepo BI, Cardona AE, McGuff HS, Teale JM. Leishmania donovani. evolution and architecture of the splenic cellular immune response related to control of infection. Exp Parasitol 2001; 99:17-25.
13. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR. The immunopathology of experimental visceral leishmaniasis. Immunol Rev 2004; 201:239-53.
14. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A, Lohmann-Matthes ML. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20:63-77.
15. Moreno J, Canavate C, Chamizo C, Laguna F, Alvar J. HIV-Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy. Trans R Soc Trop Med Hyg 2000; 94:328-32.
16. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 2000; 30:2935-43.
17. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83:1253-7.
18. Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J Infect Dis 2000; 182:1497-502.
19. Wei XQ, Niedbala W, Xu D, Luo. ZX, Pollock KG, Brewer JM. Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major infection. Immunol Lett 2004; 94:35-7.
20. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of Leishmania donovani strains to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrobiol Agents Chemother 2003; 47:1529-35.
21. Carter KC, Baillie AJ, Alexander J, Dolan TF. The therapeutic effect of sodium stibogluconate in the BALB/c mice infected with L. donovani is organ dependent. J Pharm Pharmacol 1988; 40:370-3.
22. Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage anti-leishmanial responses and trivalent antimony therapy. Parasitology 2005; 131:747-57.
23. Taylor A, Murray HW. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin 12 in experimental visceral leishmaniasis in interferon- γ gene-disrupted mice. J Exp Med 1997; 185:1231-9.
24. Murray HW. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol 2005; 174:4916-23.
25. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000; 164:1458-62.
26. Dasgupta B, Roychoudhury K, Ganguly S, Kumar Sinha P, Vimal S, Das P, Roy S. Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann Trop Med Parasitol 2003; 97:245-57.
27. 2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem 2003; 278:25120-32.
28. Wolday D, Berhe N, Britton S, Akuffo H. HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS 2000; 14:921-9.